Read More Pharma Industry News BioTheryX begins BTX-A51 phase 1 trial in AML and myelodysplastic syndrome BTX-A51 phase 1 trial : US biotech company BioTheryX has initiated patient dosing in its first clinical program… bypharmanewsdailyJanuary 19, 2020
